All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
ISB 1342 is a bispecific antibody that simultaneously targets CD38 and CD3 on multiple myeloma (MM) and T cells, respectively. Created using bispecific engagement by antibodies based on T-cell receptor (BEAT®) technology, ISB 1342 was designed to demonstrate low immunogenicity and binds to an alternative epitope on CD38 to daratumumab1. Previously known as GBR 1342, the agent received orphan drug designation in 2019 for the treatment of relapsed/refractory MM (RRMM), in the hope to overcome resistance to daratumumab.
At the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Marie-Agnès Doucey presented preclinical data surrounding ISB 1342 for the treatment of RRMM.1 The topline findings from across the preclinical studies are summarized below:
ISB 1342 represents a promising agent for the treatment of patients with RRMM, demonstrating encouraging in vitro potency and in vivo efficacy. Data from preclinical studies support the ongoing clinical evaluation of the T-cell engager: ISB 1342 is currently being evaluated in a phase I dose-escalation study (NCT03309111) in triple-class exposed/refractory patients,2 which represent a current unmet medical need.
Your opinion matters
Outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?
During the ASCO 2021 Annual Meeting, the Multiple Myeloma Hub spoke with Maria Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We...
When sequencing therapies for RRMM, how can we identify which patients may benefit most from CAR-T?
During the 2021 ASCO Annual Meeting and the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Nikhil Munshi, Dana-Farber Cancer Institute,...
Subscribe to get the best content related to multiple myeloma delivered to your inbox